Asbury United Methodist Church
Sharing Christ's Love Generation to Generation

A privately-held.

Altair announces positive Phase I results for Surroundings645 in treating asthma Altair Therapeutics, Inc., a privately-held, biopharmaceutical organization developing novel therapeutics for respiratory diseases, today announced positive results from a stage I multiple dose security and pharmacokinetic research of its lead item, once-weekly inhaled AIR645 in healthy adults and slight asthmatics propranolol generic name . Today by Dr The outcomes were presented. Michael Hodges, M.D., Chief Medical Officer for Altair Therapeutics at the European Respiratory Society Annual Congress in Vienna. AIR645 is a nonsteroidal dual inhibitor of cellular responses to interleukin -4 and IL-13.